Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (9545)	4/6/1999 11:07:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Murphy is bullish but continues fixated on the planned accruals rather than the independently arrived at mortality requirement. I was in the same boat but using 200. I do not fault Murphy for saying 125, he has corrected this. My point is I was just as wrong with my 200. I have changed my mind after Martin explained that arrival at the required mortality level will determine the number of people who participated in the trial. Yes one can use actual accruals to estimate mortality. I agree with Murphy that if Neuprex works for Meningococemia we do have big T.V. type news.